Data from Berg's Proprietary Interrogative Biology™ Platform presented at the AACR Annual Meeting 2013
FRAMINGHAM, MA, April 6, 2013 /PRNewswire/ - Berg - a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach - announced today that it will be presenting four abstracts at the AACR Annual Meeting 2013, in Washington, D.C. These data reveal key insights about cancer-cell metabolism and add to the growing body of evidence supporting the potential of Berg's proprietary Interrogative Biology™ Platform, which combines sophisticated analytics and integrated data models to understand human health and provide a broader view on diseases processes.
"These new findings provide further details into the metabolic machinery of cancer, allowing us to identify novel biomarkers and potential treatment targets," said Niven R. Narain, President, Co-Founder & Chief Technology Officer of Berg. "At Berg, we are working to understand human health more broadly and uncover solutions for diseases by mapping the first full picture of the human biology ecosystem, rather than individual disease triggers. We believe this approach has great potential to advance the treatment of cancer and other diseases."
"We are in the midst of a paradigm shift in the way we approach treating complex diseases like cancer," said Eric E. Schadt, PhD, Director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai. "Berg is heralding this shift by challenging the mold of the current scientific process and evaluating the interconnectedness of the human system, rather than singular targets."
The data from Berg being presented at the AACR Annual Meeting 2013 include the following:
- Berg Interrogative Biology™ platform unravels novel biomarkers FLNB and
LY9 in combination with PSA enhances specificity in serum of patients
with prostate cancer. Sarangarajan, R., et. al.
Poster Session: Apr 07, 2013, 1:00 PM - 5:00 PM,
Location: Hall A-C, Poster Section 1, Abstract #7, Poster Board #7 - Mitochondrial priming of apoptotic machinery in pancreatic cancer by BPM
31510 to enhance efficacy of chemotherapy.
Narain, N.R., et. al.
Poster Session: Apr 08, 2013, 1:00 PM - 5:00 PM
Location: Hall A-C, Poster Section 25, Abstract #1736, Poster Board #27 - Berg Interrogative Biology™ Informatics Suite: data driven integration
of multi-omic technologies using Bayesian AI.Rodrigues, L., et. al.
Time/Date: Wednesday, Apr 10, 2013, 8:00 AM -12:00 PM
Location: Hall A-C, Poster Section 26, Abstract # 5230, Poster Board #18 - Identification of Enolase1 as key drug target in breast cancer by the
Berg Interrogative Biology™ platform. Jing, E., et. al.
Time/Date: Wednesday, Apr 10, 2013, 8:00 AM -12:00 PM
Location: Hall A-C, Poster Section 38, Abstract # 5542, Poster Board #22
About the Berg Interrogative Biology™ Platform
Berg's application of Artificial Intelligence in biology and medicine
allows for a combination of systems biology and systems engineering
leading to well defined answers on human health. The Berg Interrogative
Biology™ Platform integrates molecular data directly from a patient
with clinical and demographic information to learn predictive patterns.
The platform has the potential to provide the physician with actionable
information to recommend efficient and safe treatment pathways,
insurance companies with health economics analyses to develop more
relevant formulary and governments with a data ecosystem for financial
modeling of healthcare needs of the population.
Using the Interrogative Biology™ Platform, the company has successfully harnessed the ability of its lead oncology candidate, BPM 31510, in development with gemcitabine, to create an anti-cancer effect. Phase 1 and 2 clinical trials of a topical formulation of BPM 31510 for the treatment of skin cancers have completed, as has a Phase 1 dose escalation clinical trial of an intravenous formulation of BPM 31510 for the treatment of solid tumors.
About Berg
Berg is a biopharmaceutical company and parent company to Berg Pharma,
Berg Biosystems and Berg Diagnostics. Our research focus seeks to
understand how alterations in metabolism relate to disease onset. We
have uncovered key insight into metabolic control factors and namely
into underlying elements in the Warburg Hypothesis. The company has a
deep pipeline of early-stage technologies in CNS diseases and metabolic
diseases that complement its late-stage clinical trial activity in
cancer and prevention of chemotoxicity. Armed with use of the discovery
platform that translates biological output into viable therapeutics and
a robust biomarker library, Berg is poised to realize its pursuit of a
healthier tomorrow.
Media Contact:
Sarah Block
Ogilvy Public Relations
212-880-5354
sarah.block@ogilvy.com
Investor Contact:
Tom Smith
Ogilvy Public Relations
212-880-5269
tom.smith@ogilvy.com
SOURCE Berg
